Pharmaceutical Product Assessment

…am expressed frustration regarding the limitations of available pharmaceuticals, specifically stating, “…is it atand supposed to be using for a baby pig. The products that are licensed are for mature, large animals…

…am expressed frustration regarding the limitations of available pharmaceuticals, specifically stating, “…is it atand supposed to be using for a baby pig. The products that are licensed are for mature, large animals…

…The study was designed Tri-Solfen (Animal Ethics) is an aqueous fixed and executed as per the CONSORT guidelines.13 Fol- combination product containing 40.6 g/L lidocaine lowing the creation…

…Pharmaceutical companies must use meth- the FDA efficacy requirement of a product. ods to assess animal responses that are well-defined and reliable to demonstrate products’ efficacy and safety when seeking FDA…

…Pharmaceutical companies must use meth- the FDA efficacy requirement of a product. ods to assess animal responses that are well-defined and reliable to demonstrate products’ efficacy and safety when seeking FDA…

…of pain relief in pigs, a product must first demonstrate efficacy as supported through clinically validated end-points [1]. Pain associated with castration can be assessed using a variety of measures, including…

…of pain relief in pigs, a product must first demonstrate efficacy as supported through clinically validated end-points [1]. Pain associated with castration can be assessed using a variety of measures, including…

m (Goods and Services Tax) Act 1999 and related legislation passed by the Federal Government; "Indication" means a specific animal welfare use-case or application of the Product for which an assessment is to be performed under Schedule 2; "Insolvency Administration" means any form of external administration of the property of any person whether under the provisions of the Corporations Law, the Bankruptcy Act 1966 or any other similar legislation or otherwise including bankruptcy, winding up, liquidation, voluntary administration and the appointment of a receiver or a receiver and manager; "Intellectual Property" means all forms of intellectual property rights throughout the world including copyright, registered patent, design, trademark and confidential information including know-how and trade secrets; "Manager" means the person described in Item 5 of Schedule 1; "Moral Rights" has the meaning given to it in the Copyright Amendment (Moral Rights) Act 2000 (Cth); "Product" means Tri-Solfen, a topical anaesthetic and antiseptic wound management product manufactured by the Client; "related company" has the meaning given to a related body corporate under the Corporations Act; "rights and claims" includes all rights, entitlements, claims, debts, actions, demands, suits, proceedings, liabilities, losses, sums of money, damages, expenses and costs; "Services" includes the services described in Schedule 2 and any additional or ancillary services agreed between the Company and the Client in writing from time to time; "Term" means the period from the Commencement Date until the Termination Date unless this Deed is extended by mutual agreement by the parties in writing or this Deed is otherwise terminated; and "Termination Date" means the date set out in Item 4 of Schedule 1. 1.2

pplied directly to the disbudding wound, Tri-Solfen® is reported to be effective to mitigate post-operative pain [7,8]. To achieve regulatory approval for such uses, analgesic medicines must meet high standards of proof of safety, requiring detailed proscribed “margin of safety” studies examining the toxic effects of drugs at recommended dose and potential overdose levels. These trials, performed to internationally harmonized standards, are nevertheless invasive and may involve ethical constraints such as the requirement for single product use, where, in non- regulatory trials, multi-modal pain therapy may be used for optimal welfare. The need for such trials is reduced however, wherever sufficient high-quality data are publicly available. Lidocaine and bupivacaine, the local anaesthetics in Tri-Solfen® , although widely used in human and veterinary medicine for many decades, are not registered for use to mitigate pain in calves in most jurisdictions. Although their acute systemic neuro- and cardiotoxic effects are well described, unfortunately, at the time of these trials, there was insufficient information available to meet regulatory requirements for proof of safety of use in calves, including lack of information regarding potential wider biochemical, haematological or tissue toxic effects, or impacts when used via topical application to significant open wounds. We therefore have performed regulatory required margin of safety studies with Tri-Solfen® and report the outcome of these to contribute to the public record. It is hoped that these data may reduce the need for such trials for registration of lidocaine or bupivacaine containing products for calves in the future. We separately investigated and reported local anaesthetic pharmacokinetic data in calves

…Therefore, identifying realistic and effective pharmaceutical products that can be approved for use on farms is needed in the US. Lack of pain management at the time of castration may also be…